At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Men Receiving Androgen Deprivation Therapy
In Brief
A Phase 2 clinical trial evaluating Oxybutynin Chloride, Placebo Administration, and 2 other interventions for Prostate Carcinoma. Completed, enrolled 88 participants across 103 sites.
Detailed Summary
This phase II trial compares the effect of oxybutynin versus placebo for reducing hot flashes in men receiving androgen deprivation (hormone) therapy for the treatment of prostate cancer . Androgen deprivation therapy decreases testosterone and other androgens through medications or surgical removal of the testicles. Relative to placebo, low- or high-dose oxybutynin may reduce hot flashes in men receiving androgen deprivation therapy.
Study Details
Timeline
Interventions
Given PO
Given PO
Ancillary studies
Ancillary studies